Donwha receives presidential award for DW-1350

Published: 2008-12-17 06:41:00

Updated: 2008-12-17 06:41:00

Dongwha Pharm said on November 11 that following DW224a (zabofloxacin), it received, for the consecutive two years, the Presidential Award in 2008 Health Industry and Technology Exhibition of Korea (HITEK) in recognition for developing and exporting a newly developed substance for a drug to cure ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK